دورية أكاديمية
أعرض في EDS

HIV-1 virologic failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya: a cross-sectional study.

التفاصيل البيبلوغرافية
العنوان: HIV-1 virologic failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya: a cross-sectional study.
المؤلفون: Hassan AS; KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya. ahassan@kemri-wellcome.org., Nabwera HM, Mwaringa SM, Obonyo CA, Sanders EJ, Rinke de Wit TF, Cane PA, Berkley JA
المصدر: AIDS research and therapy [AIDS Res Ther] 2014 Jan 23; Vol. 11 (1), pp. 9. Date of Electronic Publication: 2014 Jan 23.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101237921 Publication Model: Electronic Cited Medium: Print ISSN: 1742-6405 (Print) Linking ISSN: 17426405 NLM ISO Abbreviation: AIDS Res Ther Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [London] : BioMed Central, 2004-
مستخلص: Background: An increasing number of people on antiretroviral therapy (ART) in sub-Saharan Africa has led to declines in HIV related morbidity and mortality. However, virologic failure (VF) and acquired drug resistance (ADR) may negatively affect these gains. This study describes the prevalence and correlates of HIV-1 VF and ADR among first-line ART experienced adults at a rural HIV clinic in Coastal Kenya.
Methods: HIV-infected adults on first-line ART for ≥6 months were cross-sectionally recruited between November 2008 and March 2011. The primary outcome was VF, defined as a one-off plasma viral load of ≥400 copies/ml. The secondary outcome was ADR, defined as the presence of resistance associated mutations. Logistic regression and Fishers exact test were used to describe correlates of VF and ADR respectively.
Results: Of the 232 eligible participants on ART over a median duration of 13.9 months, 57 (24.6% [95% CI: 19.2 - 30.6]) had VF. Fifty-five viraemic samples were successfully amplified and sequenced. Of these, 29 (52.7% [95% CI: 38.8 - 66.3]) had at least one ADR, with 25 samples having dual-class resistance mutations. The most prevalent ADR mutations were the M184V (n = 24), K103N/S (n = 14) and Y181C/Y/I/V (n = 8). Twenty-six of the 55 successfully amplified viraemic samples (47.3%) did not have any detectable resistance mutation. Younger age (15-34 vs. ≥35 years: adjusted odd ratios [95% CI], p-value: 0.3 [0.1-0.6], p = 0.002) and unsatisfactory adherence (<95% vs. ≥95%: 3.0 [1.5-6.5], p = 0.003) were strong correlates of VF. Younger age, unsatisfactory adherence and high viral load were also strong correlates of ADR.
Conclusions: High levels of VF and ADR were observed in younger patients and those with unsatisfactory adherence. Youth-friendly ART initiatives and strengthened adherence support should be prioritized in this Coastal Kenyan setting. To prevent unnecessary/premature switches, targeted HIV drug resistance testing for patients with confirmed VF should be considered.
References: Lancet Infect Dis. 2009 Jul;9(7):409-17. (PMID: 19555900)
Lancet. 2008 May 10;371(9624):1603-11. (PMID: 18468544)
Lancet Infect Dis. 2011 Oct;11(10):750-9. (PMID: 21802367)
BMC Infect Dis. 2008 Jul 04;8:89. (PMID: 18601727)
Lancet Infect Dis. 2010 Mar;10(3):155-66. (PMID: 20185094)
AIDS Res Hum Retroviruses. 2008 Aug;24(8):1031-5. (PMID: 18724803)
J Antimicrob Chemother. 2013 Jun;68(6):1400-5. (PMID: 23404192)
J Antimicrob Chemother. 2006 May;57(5):803-5. (PMID: 16533823)
PLoS Comput Biol. 2009 Nov;5(11):e1000581. (PMID: 19956739)
AIDS. 2008 Oct 1;22(15):1971-7. (PMID: 18784460)
J Infect Dis. 2008 Mar 15;197(6):867-70. (PMID: 18269317)
JAMA. 2005 Feb 16;293(7):817-29. (PMID: 15713771)
J Acquir Immune Defic Syndr. 2008 May 1;48(1):104-8. (PMID: 18285709)
AIDS Res Hum Retroviruses. 2013 Jan;29(1):129-35. (PMID: 22900472)
AIDS Res Treat. 2011;2011:434375. (PMID: 21490778)
Lancet. 2012 Oct 6;380(9849):1250-8. (PMID: 22828485)
Lancet Infect Dis. 2011 May;11(5):363-71. (PMID: 21354861)
Trop Med Int Health. 2012 Jan;17(1):82-93. (PMID: 22943164)
Ann Intern Med. 2009 May 19;150(10):688-95. (PMID: 19349625)
Lancet. 2006 Nov 4;368(9547):1587-94. (PMID: 17084759)
Clin Infect Dis. 2012 May;54 Suppl 4:S294-9. (PMID: 22544190)
PLoS One. 2011 Mar 09;6(3):e17518. (PMID: 21408071)
Clin Infect Dis. 2009 Aug 1;49(3):454-62. (PMID: 19569972)
Pediatrics. 2011 Oct;128(4):762-71. (PMID: 21930548)
Lancet Infect Dis. 2012 Apr;12(4):307-17. (PMID: 22036233)
Antivir Ther. 2013;18(1):115-23. (PMID: 23052978)
J Acquir Immune Defic Syndr. 2006 Sep;43(1):78-84. (PMID: 16878045)
Methods Mol Biol. 2011;665:123-32. (PMID: 21116799)
J Acquir Immune Defic Syndr. 2011 Apr;56(4):356-64. (PMID: 21191309)
Clin Infect Dis. 2006 Jun 1;42(11):1608-18. (PMID: 16652319)
Nucleic Acids Res. 2003 Jan 1;31(1):298-303. (PMID: 12520007)
AIDS. 2009 Sep 10;23(14):1867-74. (PMID: 19531928)
Trop Med Int Health. 2009 Aug;14(8):856-61. (PMID: 19552661)
معلومات مُعتمدة: 092654 United Kingdom Wellcome Trust
تواريخ الأحداث: Date Created: 20140125 Date Completed: 20140212 Latest Revision: 20220408
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC3922732
DOI: 10.1186/1742-6405-11-9
PMID: 24456757
قاعدة البيانات: MEDLINE
كن أول من يترك تعليقا!
يجب تسجيل دخولك أولا